

1 On February 11, 2013, this Court granted Plaintiff's Motion to Reset the Effective Date of
2 the FDA's approval for the Defendants to Market Generic YAZ. (Dkt. 363.)

3 On February 12, 2013, Defendant Sandoz Inc. ("Sandoz") filed an emergency motion to stay
4 the Court's February 11 order (see Dkt. 364.) and a memorandum in support thereof ("Emergency
5 Motion to Stay"). Sandoz requested relief therein pursuant to Fed. R. Civ. P. 62(c) (Dkt. 364 at 2.)
6 and, in the alternative, pursuant to Fed. R. Civ. P. 60(b)(6).
7

8 On February 13, 2013 Defendants Watson Pharmaceuticals, Inc. and Watson Laboratories,
9 Inc. (collectively, "Watson") filed a joinder to Sandoz's Emergency Motion to Stay. (Dkt. 366.)

10 On February 28, 2013, Sandoz filed Notice of Withdrawal of the Portion of Sandoz's
11 Emergency Motion to Stay Requesting Alternative Relief Under Fed. R. Civ. P. Rule 60(b)(6).
12 (Dkt. 375.)

13 On February 28, 2013, Watson filed a Notice of Clarification and/or Partial Withdrawal of
14 Watson's Notice and Joinder of Emergency Motion as to the Portion Requesting Alternative Relief
15 Under Fed. R. Civ. P. 60(b)(6). (Dkt. 376.)
16

17 In view of the Watson notice of withdrawal as well as the Sandoz notice of withdrawal, IT
18 IS HEREBY ORDERED that Watson's motion pursuant to Fed. R. Civ. P. 60(b)(6) is hereby
19 DENIED as moot.

20 DATED this 8th day of March 2013.
21

22 

23 _____
24 Kent J. Dawson
25 United States District Judge
26
27
28
29